Ontology highlight
ABSTRACT:
SUBMITTER: Schneider BP
PROVIDER: S-EPMC4453857 | biostudies-literature | 2014 Sep
REPOSITORIES: biostudies-literature
Schneider B P BP Li L L Shen F F Miller K D KD Radovich M M O'Neill A A Gray R J RJ Lane D D Flockhart D A DA Jiang G G Wang Z Z Lai D D Koller D D Pratt J H JH Dang C T CT Northfelt D D Perez E A EA Shenkier T T Cobleigh M M Smith M L ML Railey E E Partridge A A Gralow J J Sparano J J Davidson N E NE Foroud T T Sledge G W GW
British journal of cancer 20140812 6
<h4>Background</h4>Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available for predicting bevacizumab-induced hypertension.<h4>Methods</h4>A genome-wide association study (GWAS) was performed in the phase III bevacizumab-based adjuvant breast cancer trial, ECOG-5103, to evaluate for an association between genotypes and hypertension. GWAS was conducted in those who had experienced systolic blood pressure (SBP) >160 mm Hg during therapy u ...[more]